Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system

Journal of Hypertension

Volumn 25, Issue 5, 2007, Pages 951-958

  Agodoa, L ^b   Anderson, C ^b   Asseibergs, F ^b   Baigent, C ^b   Black, H ^b   Brenner, B ^b   Brown, M ^b   Bulpitt, C ^b   Byington, R ^b   Chalmers, J ^b   Collins, R ^b   Cutler, J ^b   Dahlof, B ^b   Davis, B ^b   De Zeeuw, D ^b   Dens, J ^b   Estacio, R ^b   Fagard, R ^b   Fox, K ^b   Fukui, T ^b   Hansson, L ^b   Holman, R ^b   Hunsicker, L ^b   Imai, Y ^b   Ishii, M ^b   Kanno, Y ^b   Kostis, J ^b,b   Kuramoto, K ^b   Lewis, E ^b   Lievre M ^b   Lindholm, L H ^b   Liu, L ^b   Lubsen, J ^b   Lueders, S ^b   MacMahon, S ^b   Malacco, E ^b   Mancia, G ^b   Matsuzaki, M ^b   Neal, B ^b   Nissen, S ^b   Ohkubo, T ^b   Ogihara, T ^b   Pepine, C ^b   Pfeffer, M ^b   Pitt, B ^b   Poole Wilson, P ^b   Rahman, M ^b   Remme, W ^b   Remuzzi, G ^b   Rodgers, A ^b   Ruggenenti, P ^b   Saruta, T ^b   Schrader, J ^b   Schrier, R ^b   Sever, P ^b   Sleight, P ^b   Staessen, J ^b   Teo, K ^b   Viberti, G ^b   Wang, J ^b   Whelton, P ^b   Wing, L ^b   Yui, Y ^b   Yusuf, S ^b   Zanchetti, A ^b,b   Turnbull, F ^a   Algert, C ^b   Woodward, M ^b   more..

^a UNIVERSITY OF SYDNEY   (Australia)

^b NONE

Author keywords

Blood pressure; Coronary heart disease; Heart failure; Meta regression analyses; Metaanalyses; Stroke

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA ANALYSIS; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 34147116836     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3280bad9b4     Document Type: Article

References (45)

1. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: second cycle of prospectively designed overviews. Lancet 2003; 362:1527-1535.
2. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362:759-766.
3. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360:752-760.
4. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355:1582-1587.
5. Williams B. Recent hypertension trials: implications and controversies. J Am Coll Cardiol 2005; 45:813-827.
6. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.
7. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
8. World Health Organisation-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure lowering treatments. J Hypertens 1998; 16:127-137.
9. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: a randomized controlled trial. JAMA 2004; 292:2217-2225.
10. Marre M, Lievre M, Chatellier G, Mann JFE, Passa P, Menard J, for the DIABHYCAR Study Investigagors. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004; 328:495.
11. European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788
12. MacMahon S, Sharpe N, Gamble G, Clague A, Mhurchu CN, Clark T, et al. Randomized, placebo-controlled trial of the angiotensin converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2. Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol 2000; 36:438-443.
13. The PEACE trial investigators. Angiotensin-converting enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058-2068.
14. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
15. Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak W, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis. The Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000; 102:1748-1754.
16. Wright JT, Bakris G, Green T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421-2431.
17. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288:2981-2997.
18. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLR, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-592.
19. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-616.
20. Hansson L, Lindholm L, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension 2 study. Lancet 1999; 354:1751-1756.
21. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713-720.
22. Estacio R, Jeffers B, Hiatt W, Biggerstaff S, Gifford N, Schrier R. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998; 338:645-652.
23. Schrier R, Estacio R, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61:1086-1097.
24. Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases B (JMIC-B) randomized trial. Hypertens Res 2004; 27:181-191.
25. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
26. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
27. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al., SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875-886.
28. Julius S, Kjeldsen SE, Weber M, Brunne HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.
29. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767-771.
30. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting- enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362:772-776.
31. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362:777-781.
32. Cohn J, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomised trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675.
33. Warnica J, Gilst W, Baillot R. Ischemia Management with Accupril past bypass Graft via Inhibition of angiotensin coNverting Enzyme (IMAGINE): a multicentre randomized trial-design and rationale. Can J Cardiol 2001; 87:1058-1063.
34. Pitt B, O'Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001; 87:1058-1063.
35. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283:1967-1975.
36. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis:a randomized controlled trial. JAMA 2001; 285:2719-2728.
37. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1906.
38. Woodward M. Epidemiology: study design and data analysis, 2nd ed. Boca Raton: Chapman and Hall/CRC Press; 2005.
39. Messerli FH, White WB, Staessen JA. If only cardiologists did properly measure blood pressure. Blood pressure recordings in daily practice and clinical trials. J Am Coll Cardiol 2002; 40:2201-2203.
40. McDonald MA, Simpson SH, Ezekowitz JA, Gynes G, Tsuyuki RT. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 2005; 331:873.
41. Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens 2005; 12:2113-2118.
42. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004; 329:1248-1249.
43. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356:1955-1964.
44. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, et al., ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148:52-61.
45. Gradman A, Schmieder R, Lins R, Nussberger J, Chiang Y, Bedigian M. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111:1012-1018.